Huahai Pharmaceutical Subsidiaries Receive NMPA Approval for Clinical Trials of HB0025 Injection in Combination with HB0030 Injection for Advanced Solid Tumors

Huahai Pharmaceutical (600521.SH) announced that its subsidiaries, Shanghai Huaota Biopharmaceutical Co., Ltd. and Huabo Biopharm Co., Ltd., have received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA) for the approval of HB0025 injection combined with HB0030 injection for the treatment of advanced non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), colorectal cancer (CRC), and other types of advanced solid tumors.